Organic compounds -- part of the class 532-570 series – Organic compounds – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2002-08-29
2004-07-27
Desai, Rita (Department: 1625)
Organic compounds -- part of the class 532-570 series
Organic compounds
Heterocyclic carbon compounds containing a hetero ring...
C514S469000
Reexamination Certificate
active
06768011
ABSTRACT:
The present invention relates to a method for the preparation of the well-known antidepressant drug citalopram, 1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-5-isobenzofurancarbonitrile.
BACKGROUND OF THE INVENTION
Citalopram is a well-known antidepressant drug that has now been on the market for some years and has the following structure:
It is a selective, centrally acting serotonin (5-hydroxytryptamine; 5-HT) reuptake inhibitor, accordingly having antidepressant activities. The antidepressant activity of the compound has been reported in several publications, eg. J. Hyttel.
Prog. Neuro
-
Psychopharmacol. & Biol. Psychiat.
1982, 6, 277-295 and A. Gravem
Acta Psychiatr. Scand.
1987, 75, 478-486. The compound has further been disclosed to show effects in the treatment of dementia and cerebrovascular disorders, EP-A-474580.
Citalopram was first disclosed in DE 2,657,013, corresponding to U.S. Pat. No. 4,136,193. This patent publication describes the preparation of citalopram by one method and outlines a further method which may be used for preparing citalopram.
According to the process described, the corresponding 1-(4-fluorophenyl)-1,3-dihydro-5-isobenzofurancarbonitrile is reacted with 3-(N,N-dimethylamino)propyl-chloride in the presence of methylsulfinylmethide as condensing agent. The starting material was prepared from the corresponding 5-bromo derivative by reaction with cuprous cyanide.
International patent application No. WO 98/019511 discloses a process for the manufacture of citalopram wherein a (4-(cyano, alkyloxycarbonyl or alkylaminocarbonyl)-2-hydroxymethylphenyl-(4-fluorophenyl)methanol compound is subjected to ring closure. The resulting 5-(alkyloxycarbonyl or alkylaminocarbonyl)-1-(4-fluorophenyl)-1,3-dihydroisobenzofuran is converted to the corresponding 5-cyano derivative and the 5-cyano derivative is then alkylated with a (3-dimethylamino)propylhalogenide in order to obtain citalopram.
It has now, surprisingly, been found that citalopram may be manufactured by a novel favourable process.
The alkylation process according to the invention is particularly advantageous because the formation of by-products by polymerisation of the alkylating agent is avoided whereby a reduction in the amount of alkylating reagent to be used is made possible. The process of the invention also provides high yields.
SUMMARY OF THE INVENTION
Accordingly, the present invention relates to a method for the preparation of citalopram comprising reaction of a compound of formula
with a compound having the formula
wherein R is halogen or —O—SO
2
—X wherein X is alkyl, alkenyl, alkynyl or optionally alkyl substituted aryl or aralkyl and R
1
is dimethylamino, halogen or —O—SO
2
—X wherein X is as defined above, provided that R is not halogen when R
1
is dimethylamino;
and if R
1
is dimethylamino followed by isolation of citalopram base or a pharmaceutically acceptable acid addition salt thereof, and if R
1
is halogen or —O—SO
2
-X wherein X is as defined above, followed by conversion of the resulting compound of formula
wherein R
2
is halogen or a group of formula —O—SO
2
—X, wherein X is as defined above, to citalopram, followed by isolation of citalopram base or a pharmaceutically acceptable acid addition salt thereof.
Thus in one embodiment, the present invention relates to a method where a compound of formula (II) is reacted with a compound of formula (III) wherein R is —O—SO
2
—X wherein X is as defined above and R
1
is dimethylamino resulting in the direct formation of citalopram.
In a second embodiment, the present invention relates to a method where a compound of formula (II) is reacted with a compound of formula (III) wherein R and R
1
are independently selected from halogen and —O—SO
2
—X. The resulting compound of formula (IV) wherein R
2
is halogen or a group of formula —O—SO
2
—X, where X is as defined above, is then converted to citalopram by reaction with
a) dimethylamine or a metal salt thereof,
b) methylamine followed by reductive amination, or
c) an azide followed by reduction to form the corresponding amino compound and thereafter methylation or reductive amination.
In another aspect, the present invention provides the novel intermediates of the general formula (IV).
In yet another aspect, the present invention relates to an antidepressant pharmaceutical composition comprising citalopram manufactured by the process of the invention.
The alkylation step where the compound of formula (II) is reacted with a compound of formula (III) is suitably carried out by treatment of the compound of formula (II) with a base such as for example LDA (lithium diisopropylamine), LiHMDS (lithium hexamethyldisilazane), NaH, NaHMDS (sodium hexamethyldisilazane), or metalalkoxides such as NaOMe, KOMe, LiOMe, NaOtertBu, KOtertBu and LiOtertBu in an aprotic organic solvent such as THF (tetrahydrofuran), DMF (dimethylformamide), NMP (N-methylpyrrolidon), ethers such as diethylether, or dioxalane, toluene, benzene or alkanes and mixtures thereof. The anion formed is then reacted with a compound of formula (III) whereby a group of formula —CH
2
—CH
2
—CH
2
—R
2
or a group of formula —CH
2
—CH
2
—CH
2
—N(CH
3
)
2
is introduced into position 1 of the isobenzofuranyl ring system.
The compound of formula (IV) is then reacted with dimethylamine or a metal salt thereof, such as M
+
, —N(CH
3
)
2
wherein M
+
is Li
+
or Na
+
. The reaction is suitably carried out in an aprotic organic solvent such as THF (tetrahydrofuran), DMF (dimethylformamide), NMP (N-methyl pyrrolidon), ethers such as diethylether, or dioxalane, toluene, benzene, or alkanes and mixtures thereof. The compound of formula (IV) may also be converted to citalopram by reaction with dimethylammonium chloride.
The reaction conditions, solvents, etc. used for the reactions described above are conventional conditions for such reactions and may easily be determined by a person skilled in the art.
Alternatively, the compound of formula (IV) is reacted with an azide, such as sodium azide, followed by reduction, using e.g. Pd/C as a catalyst, to form the corresponding amine of formula
and thereafter methylation or reductive amination to form citalopram.
The compound of formula (IV) may also be converted to citalopram by reaction with methylamine to form a compound of formula
followed by methylation or reductive amination to form citalopram.
The amino groups in the compounds of formula (V) and (VI) may be methylated with methylating agents such as Mel and Me
2
SO
4
wherein Me is methyl. The methylation is carried out using conventional procedures for carrying out such reactions.
Methyl groups may also be introduced into the compounds of formula (V) or (VI) by reductive amination. According to this procedure, the compounds of formula (V) or (VI) are reacted with compounds such as formaldehyde, paraformaldehyde or trioxan in presence of a reducing agent such as NaBH
4
or NaBH
3
CN. The reductive amination is carried out using conventional procedures for carrying out such reactions.
The starting material of formula (II) may be prepared as described in U.S. Pat. No. 4,136,193 or as described in WO 98/019511.
The compounds of formula (III) are known or may be prepared from known compounds using conventional methods.
Citalopram is on the market as an antidepressant drug in the form of the racemate. However, in the near future, the active S-enantiomer of citalopram is also going to be introduced to the market.
S-citalopram may be prepared by separation of the optically active isomers by chromatography.
Throughout the specification and claims, the term alkyl refers to a branched or unbranched alkyl group having from one to six carbon atoms inclusive, such as methyl, ethyl, 1-propyl, 2-propyl, 1-butyl, 2-butyl, 2-methyl-2-propyl, 2,2-dimethyl-1-ethyl and 2-methyl-1-propyl.
Similarly, alkenyl and alkynyl, respectively, designate such groups having from two to six carbon atoms, including one double bond or triple bond respectively, such as ethenyl, propenyl, butenyl, ethynyl, propynyl and butynyl
Ahmadian Haleh
Rock Michael Harold
Covington Raymond
Darby & Darby
Desai Rita
H. Lundbeck A/S
LandOfFree
Method for the preparation of citalopram does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for the preparation of citalopram, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for the preparation of citalopram will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3216224